CML Gene-Edited Cell Lines for Drug Discovery and Research

Chronic Myelogenous Leukemia (CML) accounts for approximately 15% of all adult leukemias, with an annual global incidence of 1-2 cases per 100,000 individuals (WHO, 2023). The median age at diagnosis is 64 years, and the disease is slightly more common in males. With the advent of tyrosine kinase inhibitors (TKIs), the 5-year relative survival rate has improved dramatically to over 90% for chronic phase CML, but drops to less than 50% for blast phase (NCI SEER, 2023). Key risk factors include exposure to high-dose radiation, but most cases arise spontaneously. The major clinical challenge remains TKI resistance, particularly in advanced phases, driving the need for new therapeutic strategies.

CML is an ideal model for studying oncogene addiction and targeted therapy resistance because it is driven by a single, well-defined genetic event: the BCR-ABL1 fusion gene (Philadelphia chromosome). This simplicity allows researchers to dissect resistance mechanisms, test novel inhibitors, and explore synthetic lethality. Public datasets from TCGA and COSMIC provide extensive mutation and expression profiles, while the DepMap project offers CRISPR dependency data for CML cell lines. Open questions include the role of BCR-ABL1-independent resistance pathways and the development of therapies effective against the T315I gatekeeper mutation.

The BCR-ABL1 fusion protein is a constitutively active tyrosine kinase that drives CML pathogenesis through several pathways:

1. RAS/MAPK Pathway: BCR-ABL1 activates RAS, leading to RAF-MEK-ERK signaling, promoting cell proliferation.

2. PI3K/AKT Pathway: Direct activation of PI3K by BCR-ABL1 leads to AKT phosphorylation, enhancing cell survival and metabolism.

3. JAK-STAT Pathway: BCR-ABL1 phosphorylates STAT5, which upregulates anti-apoptotic genes like BCL-XL.

4. MYC Pathway: BCR-ABL1 stabilizes MYC protein, driving cell cycle progression.

These pathways are interconnected and contribute to the uncontrolled proliferation and resistance to apoptosis characteristic of CML cells.

Data from TCGA and COSMIC (v99).

Key deregulated networks in CML include:

• • BCR-ABL1 Signaling Hub: Central node that activates multiple downstream pathways.
• • PI3K/AKT/mTOR Network: Promotes survival and protein synthesis.
• • Key nodes: PI3K, AKT, mTOR, S6K.
• • RAS/RAF/MEK/ERK Network: Drives proliferation.
• • Key nodes: KRAS, BRAF, MEK1/2, ERK1/2.
• • JAK/STAT Network: Upregulates anti-apoptotic genes.
• • Key nodes: JAK2, STAT5, BCL-XL.
• • Wnt/beta-Catenin Network: Involved in self-renewal of leukemic stem cells.
• • Key nodes: beta-catenin, LEF/TCF, AXIN2.

Organoid models for CML are emerging but less established than for solid tumors. They offer the advantage of preserving the 3D architecture and microenvironment interactions, enabling studies of leukemic stem cell niche and drug response.

Animal models for CML include:

• • Patient-Derived Xenograft (PDX) Models: Engraftment of human CML cells into immunodeficient mice (e.g., NSG). Useful for testing TKI efficacy and resistance.
• • Genetically Engineered Mouse Models (GEMMs): Transgenic mice expressing BCR-ABL1 under a hematopoietic-specific promoter (e.g., SCL). Develop CML-like disease.
• • Induced Models: Retroviral transduction of BCR-ABL1 into mouse bone marrow cells followed by transplantation into irradiated recipients. Allows study of disease progression and stem cell biology.

CRISPR/Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications, such as:

• • BCR-ABL1 Knockout: Eliminates the fusion gene to study oncogene addiction.
• • ABL1 Kinase Domain Mutations (e.g., T315I): Introduces resistance mutations to model TKI failure.
• • TP53 Knockout: Models blast phase progression.
• • Reporter Lines (e.g., BCR-ABL1-GFP): Enables live-cell tracking and drug screening.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing clean, reproducible systems for target validation and drug development. These models are typically validated by Sanger sequencing, western blot, and functional assays.

Gene-edited cell lines are essential for functional genomics in CML. For example:

• • BCR-ABL1 knockout in K562 cells confirms its role in maintaining proliferation and survival.
• • TP53 knockout in BCR-ABL1-positive cells demonstrates its role in genomic stability and response to DNA damage.
• • RUNX1 knockout models the differentiation block seen in blast phase CML.

These models allow researchers to dissect the contribution of individual genes to disease phenotypes.

Isogenic pairs (e.g., parental vs. T315I-mutant K562) are powerful tools for drug screening:

• • Differential Sensitivity: Identify compounds that retain activity against resistant mutants.
• • Combination Screens: Test synergistic effects of TKIs with other agents (e.g., BCL-2 inhibitors).
• • Resistance Modeling: Serial exposure of isogenic cells to sub-lethal drug concentrations can reveal acquired resistance mechanisms.

Such screens have identified novel therapeutic targets like AURKA and CDK2.

CRISPR-based screens in CML cell lines can identify synthetic lethal partners of BCR-ABL1. For example:

• • Genome-wide CRISPR knockout screens in K562 cells have identified genes whose loss is selectively lethal in BCR-ABL1-dependent cells, such as BCL2L1 and MCL1.
• • Targeted screens for resistance modifiers have uncovered roles for drug efflux pumps (e.g., ABCB1) and alternative signaling pathways (e.g., FGFR).

These biomarkers can be used to predict patient response and guide therapy selection.